HIV 2 VACCINES PROTECTION FROM VIRAL CHALLENGE

HIV 2 疫苗可预防病毒攻击

• 批准号: 6116342
• 负责人: William Randall Morton
• 金额: $ 8.67万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116342
• 关键词: AIDS; Mammalia; Primates; immunology; infection; inflammation; lymphatic system; model design /development; sexually transmitted diseases; vaccines; virus

This project is divided into two groups. Both groups were inoculated with HIV-2/KR, a non-pathogenic molecular clone group 1 on 6/14/94 and group 2 on 8/30/94. Group 1 was challenged twice with HIV-2/287, a highly pathogenic isolate derived from in vivo passage in Macaca nemestrina. The first challenge dose, 10 TCID (8/18/95), produced only limited infection. The second challenge dose, 1000 TCID (6/17/96), infected the nave macaques, but produced little to no infection in the macaques previously exposed. The single exception, macaque L93210, was depleted of CD4+ cells by 10 weeks post-inoculation. One macaque died of acute gastric dilatation; one was euthanatized due to deterioration in a femoral joint that compromised use of the leg. Neither death appeared related to the experimental interventions. The second group of macaques was challenged with 100 TCID (10/8/96). Although all the macaques were infected, three of the seven macaques previously exposed to the KR clone did not develop depletion of the CD4+ cells up to 64 weeks post-challenge. This project is now closed and the macaques will be necropsied for histological examination.

该项目分为两组。 两组用HIV-2/KR接种，这是6/14/94的非致病分子克隆组1，在8/30/94接种了第2组。 HIV-2/287两次对第1组进行了挑战，这是一种来自Macaca Nemestrina的体内通道的高度致病分离株。 第一个挑战剂量为10 TCID（8/18/95），仅产生有限的感染。 第二次挑战剂量为1000 TCID（6/17/96），感染了猕猴，但在先前暴露的猕猴中几乎没有感染。 单个例外是猕猴L93210，在接种后10周将CD4+细胞耗尽。 一个猕猴死于急性胃扩张。一个因股关节恶化而被安乐死的，股关节损害了腿的使用。 这两种死亡似乎都与实验干预有关。第二组猕猴受到100 TCID（10/8/96）的挑战。 尽管所有猕猴都被感染了，但先前暴露于KR克隆的七个猕猴中有三个并未在挑战后64周出现CD4+细胞的耗竭。 该项目现已关闭，猕猴将被尸检进行组织学检查。